查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1614031

Dravet 症候群市場：按產品、癲癇類型、嚴重程度、按最終用戶 - 2025-2030 年全球預測

Dravet Syndrome Market by Offering (Diagnosis & Testing Solutions, Dietary Therapies, Medications), Seizure Type (Atonic Seizures, Myoclonic Seizures, Partial seizures), Severity, End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

Dravet 症候群市場價值 2023 年為 6.7647 億美元，預計到 2024 年將達到 7.3404 億美元，複合年成長率為 8.70%，到 2030 年將達到 12.1321 億美元。

Dravet 症候群是一種罕見且具破壞性的癲癇症，始於兒童時期，其特徵是頻繁、長時間的癲癇發作和發育遲緩。 Dravet 症候群治療的市場範圍包括藥物、診斷工具和支持性護理技術。這種需求源於患者複雜且高度未滿足的醫療需求，推動了對有效藥物和管理解決方案的需求。它的許多用途是抗驚厥藥，例如芬氟拉明，以及針對潛在遺傳原因的治療方法。最終用途包括尋求透過創新解決方案最佳化患者治療結果的醫院、診所和研究機構。市場成長的關鍵影響因素包括基因研究的進步、意識的提高以及對鼓勵開發和核准新治療方法的醫療保健政策的支持。對基因治療和生物製藥創新的持續投資帶來了潛在的商機。可以透過優先考慮與生物技術公司和學術研究機構建立強力的夥伴關係關係來利用這些機會，以創造尖端的治療方法。然而，高昂的研發成本、嚴格的監管以及可參與臨床試驗的患者數量的限制等挑戰構成了重大障礙。有效應對這些挑戰需要對策略聯盟和簡化監管流程的技術進行投資。此外，創新和研究的理想領域包括尋找候選藥物、非侵入性診斷工具和遠端醫療解決方案，以增加獲得醫療保健的機會。對這個市場的深入了解揭示了其高成長潛力，這主要歸功於活躍的研發活動和對有效治療方法的強烈需求。然而，與現有治療方法的競爭、某些地區公眾意識較低以及報銷問題正在阻礙成長。公司可以透過開拓這些創新領域、最佳化其分銷網路以及增加對醫療保健提供者和患者的教育舉措來加速其市場成功。整體而言，Dravet 綜合症市場對於敏捷醫療保健公司正面應對多方面挑戰具有充足的成長潛力。

主要市場統計
基準年[2023] 67647萬美元
預測年份 [2024] 73404萬美元
預測年份 [2030] 12.1321億美元
複合年成長率（%） 8.70%

市場動態：揭示快速發展的 Dravet 症候群市場的關鍵市場洞察

Dravet 症候群市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 增加旨在闡明遺傳疾病的研發活動
    • 人們對罕見疾病的認知不斷增強
    • 為開發藥物和治療 Dravet 症候群的藥物提供支持性法規環境
  • 市場限制因素
    • Dravet 症候群相關治療費用上漲
  • 市場機會
    • Dravet 症候群治療與藥物的基因治療進展
    • 增加對罕見疾病研究的資助
  • 市場挑戰
    • 診斷挑戰導致誤診和延誤正確診斷

波特的五力：駕馭 Dravet 症候群市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解 Dravet 症候群市場的外部影響

外部宏觀環境因素在塑造 Dravet 症候群市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解 Dravet 症候群市場的競爭格局

對 Dravet 綜合症市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

Dravet 症候群市場供應商針對 FPNV 定位矩陣的績效評估

FPNV 定位矩陣是評估 Dravet 症候群市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了 Dravet 症候群市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對 Dravet 症候群市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告提供了涵蓋關鍵重點領域的市場全面分析：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、未開發地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 增加旨在了解遺傳疾病的研究和開發活動
      • 人們對罕見疾病的認知不斷增強
      • 支持 Dravet 症候群治療方法和藥物開發的法規環境
    • 抑制因素
      • Dravet 症候群相關治療費用上漲
    • 機會
      • Dravet 症候群治療方法與藥物基因治療的進展
      • 增加對罕見疾病研究的資助
    • 任務
      • 診斷挑戰會導致誤診和正確診斷的延誤。
  • 市場區隔分析
    • 提供者：分發藥物來控制癲癇發作並減少癲癇發作頻率
    • 最終用途：醫院在急診和管理以及提供專業設備方面的關鍵作用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第 6 章 Dravet 症候群市場：透過提供

  • 診斷和測試解決方案
    • 腦電波
    • 基因檢測
    • MRI 和電腦斷層掃描
  • 飲食療法
  • 藥品
    • Clobazam
    • 司替戊醇
    • 丙戊酸

第 7 章 Dravet 症候群市場：依癲癇類型

  • 失張力發作
  • 肌陣攣發作
  • 局部性發作
  • 光敏性癲癇發作
  • 強直陣攣發作

第 8 章 Dravet 症候群市場：依嚴重程度

  • 溫和的
  • 適度
  • 嚴重

第 9 章 Dravet 症候群市場：依最終用途

  • 居家護理
  • 醫院
  • 專科診所

第10章美洲Dravet症候群市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章 亞太地區Dravet症候群市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲Dravet症候群市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • STK-001在管理上的突破性功效：臨床試驗綜合分析及未來展望
    • FDA 和 TGA核准將 Encoded Therapeutics 的基因療法 ETX101 納入 Dravet 症候群的臨床試驗
    • 腸腦軸研究取得突破：Bloom Science 的 BL-001 在治療 Dravet 症候群和 ALS 方面顯示出有希望的 1 期試驗結果
  • 戰略分析和建議

公司名單

  • Biocodex SA
  • Bloom Science, Inc.
  • Cyberonics, Inc.
  • Eisai Co., Ltd.
  • Encoded Therapeutics
  • Epygenix Therapeutics
  • GW Pharmaceuticals by Jazz Pharmaceuticals plc
  • Insys Therapeutics, Inc.
  • Longboard Pharmaceuticals, Inc.
  • OPKO Health Inc.
  • Ovid Therapeutics Inc.
  • PTC Therapeutics
  • Sage Therapeutics
  • Stoke Therapeutics
  • Supernus Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Virpax Pharmaceuticals
  • Xenon Pharmaceuticals
  • Zogenix Inc by UCB
Product Code: MRR-4D00F1312C81

The Dravet Syndrome Market was valued at USD 676.47 million in 2023, expected to reach USD 734.04 million in 2024, and is projected to grow at a CAGR of 8.70%, to USD 1,213.21 million by 2030.

Dravet Syndrome is a rare, catastrophic form of epilepsy that begins in early childhood, characterized by frequent, prolonged seizures and developmental delays. The market scope for Dravet Syndrome treatment encompasses pharmaceuticals, diagnostic tools, and supportive care technologies. The necessity arises from the complex, high unmet medical needs of patients, driving demand for effective medications and management solutions. Applications mostly revolve around anti-seizure medications like Fenfluramine and therapies targeting the underlying genetic causes. The end-use scope spans hospitals, clinics, and research institutions eager to optimize patient outcomes through innovative solutions. Key influencing factors for market growth include advancements in genetic research, increasing awareness, and supportive healthcare policies that encourage development and approval of novel treatments. The ongoing investments in gene therapy and biopharmaceutical innovations present potential opportunities. These opportunities can be leveraged by prioritizing robust partnerships with biotech firms and academic research entities to create cutting-edge therapies. However, challenges such as high R&D costs, stringent regulatory frameworks, and limited availability of patients for clinical trials pose significant barriers. Navigating these effectively requires strategic collaborations and investment in technologies that streamline regulatory processes. Moreover, the best areas for innovation and research include exploring new drug candidates, non-invasive diagnostic tools, and telemedicine solutions that enhance healthcare accessibility. Insights into this market reveal its high-growth nature, primarily driven by intense R&D activities and a strong demand for effective remedies. Nevertheless, competition from existing treatment options, limited public awareness in some regions, and reimbursement issues are hurdles to growth. Companies can foster market success by tapping into these innovative areas, optimizing distribution networks, and enhancing education initiatives geared towards healthcare providers and patients. Overall, the Dravet Syndrome market presents ample growth potential for agile healthcare companies ready to meet the multifaceted challenges head-on.

KEY MARKET STATISTICS
Base Year [2023] USD 676.47 million
Estimated Year [2024] USD 734.04 million
Forecast Year [2030] USD 1,213.21 million
CAGR (%) 8.70%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dravet Syndrome Market

The Dravet Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in research and development activities aimed at understanding genetic disorders
    • Rising awareness of rare diseases
    • Supportive regulatory environments for developments in Dravet syndrome therapies and medications
  • Market Restraints
    • High cost of treatment associated with Dravet syndrome
  • Market Opportunities
    • Advancements in genetic therapy for Dravet syndrome therapies and medications
    • Increased funding for rare disease research
  • Market Challenges
    • Diagnostic challenges leading to misdiagnosis or delays in correct diagnosis

Porter's Five Forces: A Strategic Tool for Navigating the Dravet Syndrome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dravet Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dravet Syndrome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dravet Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dravet Syndrome Market

A detailed market share analysis in the Dravet Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dravet Syndrome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dravet Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dravet Syndrome Market

A strategic analysis of the Dravet Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dravet Syndrome Market, highlighting leading vendors and their innovative profiles. These include Biocodex S.A., Bloom Science, Inc., Cyberonics, Inc., Eisai Co., Ltd., Encoded Therapeutics, Epygenix Therapeutics, GW Pharmaceuticals by Jazz Pharmaceuticals plc, Insys Therapeutics, Inc., Longboard Pharmaceuticals, Inc., OPKO Health Inc., Ovid Therapeutics Inc., PTC Therapeutics, Sage Therapeutics, Stoke Therapeutics, Supernus Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Virpax Pharmaceuticals, Xenon Pharmaceuticals, and Zogenix Inc by UCB.

Market Segmentation & Coverage

This research report categorizes the Dravet Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Offering, market is studied across Diagnosis & Testing Solutions, Dietary Therapies, and Medications. The Diagnosis & Testing Solutions is further studied across Electroencephalogram, Genetic Testing, and MRI & CT Scans. The Medications is further studied across Clobazam, Stiripentol, and Valproate.
  • Based on Seizure Type, market is studied across Atonic Seizures, Myoclonic Seizures, Partial seizures, Photosensitive Seizures, and Tonic-Clonic Seizures.
  • Based on Severity, market is studied across Mild, Moderate, and Severe.
  • Based on End-Use, market is studied across Homecare, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in research and development activities aimed at understanding genetic disorders
      • 5.1.1.2. Rising awareness of rare diseases
      • 5.1.1.3. Supportive regulatory environments for developments in Dravet syndrome therapies and medications
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment associated with Dravet syndrome
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in genetic therapy for Dravet syndrome therapies and medications
      • 5.1.3.2. Increased funding for rare disease research
    • 5.1.4. Challenges
      • 5.1.4.1. Diagnostic challenges leading to misdiagnosis or delays in correct diagnosis
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offering: Proliferation of medications to manage & reduce the frequency of seizures
    • 5.2.2. End-Use: Pivotal role of hospitals in treating and managing acute episodes and providing access to specialized equipment
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Dravet Syndrome Market, by Offering

  • 6.1. Introduction
  • 6.2. Diagnosis & Testing Solutions
    • 6.2.1. Electroencephalogram
    • 6.2.2. Genetic Testing
    • 6.2.3. MRI & CT Scans
  • 6.3. Dietary Therapies
  • 6.4. Medications
    • 6.4.1. Clobazam
    • 6.4.2. Stiripentol
    • 6.4.3. Valproate

7. Dravet Syndrome Market, by Seizure Type

  • 7.1. Introduction
  • 7.2. Atonic Seizures
  • 7.3. Myoclonic Seizures
  • 7.4. Partial seizures
  • 7.5. Photosensitive Seizures
  • 7.6. Tonic-Clonic Seizures

8. Dravet Syndrome Market, by Severity

  • 8.1. Introduction
  • 8.2. Mild
  • 8.3. Moderate
  • 8.4. Severe

9. Dravet Syndrome Market, by End-Use

  • 9.1. Introduction
  • 9.2. Homecare
  • 9.3. Hospitals
  • 9.4. Specialty Clinics

10. Americas Dravet Syndrome Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Dravet Syndrome Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Dravet Syndrome Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Breakthrough Efficacy of STK-001 in Dravet Syndrome Management: A Comprehensive Analysis of Clinical Trials and Future Prospects
    • 13.3.2. FDA and TGA Approval Ushers Encoded Therapeutics' Gene Therapy ETX101 into Clinical Trials for Dravet Syndrome
    • 13.3.3. Breakthrough in Gut-Brain Axis Research: Bloom Science's BL-001 Shows Promising Phase 1 Results for Treatment of Dravet Syndrome and ALS
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Biocodex S.A.
  • 2. Bloom Science, Inc.
  • 3. Cyberonics, Inc.
  • 4. Eisai Co., Ltd.
  • 5. Encoded Therapeutics
  • 6. Epygenix Therapeutics
  • 7. GW Pharmaceuticals by Jazz Pharmaceuticals plc
  • 8. Insys Therapeutics, Inc.
  • 9. Longboard Pharmaceuticals, Inc.
  • 10. OPKO Health Inc.
  • 11. Ovid Therapeutics Inc.
  • 12. PTC Therapeutics
  • 13. Sage Therapeutics
  • 14. Stoke Therapeutics
  • 15. Supernus Pharmaceuticals, Inc.
  • 16. Takeda Pharmaceutical Company Limited
  • 17. Virpax Pharmaceuticals
  • 18. Xenon Pharmaceuticals
  • 19. Zogenix Inc by UCB

LIST OF FIGURES

  • FIGURE 1. DRAVET SYNDROME MARKET RESEARCH PROCESS
  • FIGURE 2. DRAVET SYNDROME MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DRAVET SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. DRAVET SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. DRAVET SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DRAVET SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DRAVET SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DRAVET SYNDROME MARKET DYNAMICS
  • TABLE 7. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ELECTROENCEPHALOGRAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MRI & CT SCANS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIETARY THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ATONIC SEIZURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MYOCLONIC SEIZURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PARTIAL SEIZURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PHOTOSENSITIVE SEIZURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TONIC-CLONIC SEIZURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 283. DRAVET SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 284. DRAVET SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023